New cancer treatment targets both tumor cells and blood vessels

MU researchers develop nontoxic treatment that has broad anti-cancer potential
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough. Now, in a new study, University of Missouri researchers have developed a new non-toxic treatment that effectively reduces breast cancer cells, by combining a small molecular drug that targets tumor cells with an antibody that causes selective shutdown of tumor blood vessels.

In 50 percent of breast cancer cases, a mutated protein, known as p53, is present. Previous research has indicated that when p53 is functionally abnormal, tumor cells are prolific and develop quickly. PRIMA-1, a small molecular drug, targets and returns normal function to the mutated p53, but PRIMA-1 alone is not enough to stop tumor growth. Proliferating blood vessels supply oxygen and other nutrients that the tumor needs to grow. However, a specific antibody, 2aG4, has the ability to destroy these blood vessels and prevent future growth. According to the MU research team, no one has previously tried to attack tumor cells by targeting mutated p53 and the tumor-associated blood vessels with this combination of PRIMA-1 and 2aG4.

"Tumors are entities that want to live," said Salman Hyder, professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "They adapt under conditions that would cause anything else to die. In order to effectively treat tumors, treatments must attack the breast tumor cells and the blood vessels that supply nutrients to the tumor. Treatment strategies in our study that targeted both areas resulted in improved and more potent responses."

In the pre-clinical trials, mice bearing tumors of human origin were given the drug combination to combat tumor growth. After four weeks of treatment, the mice that were given the combination showed a dramatic decrease in the development of tumors and had better results than the mice that were given only one of the compounds. In addition, the treatment combination proved to be non-toxic as the mice maintained their body weight and displayed few side effects.

"Mutated p53 in tumor cells plays a key role in promoting tumor cell survival and tumor cell resistance to chemotherapeutic drugs. The mutated protein is found in 50 percent of breast cancer cases," Hyder said. "The results of this study are very promising and show the possibility of broad anti-cancer potential."

Source: University of Missouri-Columbia

Related stories:

Early onset gene for inflammatory bowel diseases identified
A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment. The findings of the international team that performed the study were published online this week by the journal Nature Genetics.
Potential diabetes treatment selectively kills autoimmune cells from human patients
In experiments using blood cells from human patients with diabetes and other autoimmune disorders, Massachusetts General Hospital (MGH) researchers have confirmed the mechanism behind a potential new therapy for type 1 diabetes. A team led by Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory, showed that blocking a metabolic pathway regulating the immune system specifically eliminated immune cells that react against a patient's own tissues.
Normalizing tumor vessels to improve cancer therapy
Chemotherapy drugs often never reach the tumors they're intended to treat, and radiation therapy is not always effective, because the blood vessels feeding the tumors are abnormal—"leaky and twisty" in the words of the late Judah Folkman, MD, founder of the Vascular Biology program at Children's Hospital Boston.
Drug/radiation combo may help shrink established tumors
Researchers may be closer to understanding why anti-cancer drugs such as Ipilimumab, which boost the tumor-killing power of immune cells, haven't fared well in clinical trials. The new study, which describes a way to enhance the ability of these drugs to shrink well-established tumors, will be published online on August 25th in the Journal of Experimental Medicine.
Drugs to inhibit blood vessel growth show promise in rat model of deadly brain tumor
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.


Researcher aim to 'unmask' cancer cells to trigger body's immune system
Cancer cells are deadly traitors, good cells gone bad. They evade the body's defense systems, passing themselves off as organisms that pose no threat.
New insights into the regulation of PTEN tumor suppression function
The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types of human cancer that PTEN has become one of the most frequently mutated of all tumor suppressors.
Researcher develops novel method to grow human embryonic stem cells
(PhysOrg.com) -- The majority of researchers working with human embryonic stem cells (hESCs) – cells which produce any type of specialized adult cells in the human body – use animal-based materials for culturing the cells. But because these materials are animal-based, they could transmit viruses and other pathogens to the hESCs, making the cells unsuitable for medical use.

News discussion:

Medicine & Health news